Genetic variations and their influence on risk and treatment of venous thrombosis

Pharmacogenomics

Volumn 9, Issue 4, 2008, Pages 423-437

  Leitner, Judith Maria ^a   Mannhalter, Christine ^a   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Coagulation factors; Genetic testing mutation; Pharmacogenomics; Polymorphism; Thrombophilia; Thrombosis; Venous

Indexed keywords

5 METHYLTETRAHYDROFOLATE HOMOCYSTEINE METHYLTRANSFERASE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTITHROMBIN; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; C REACTIVE PROTEIN; COUMARIN; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; ENDOTHELIAL PROTEIN C RECEPTOR; FIBRINOGEN; PADGEM PROTEIN; PROTEIN C; PROTHROMBIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); WARFARIN;

ANTICOAGULATION; ANTITHROMBIN DEFICIENCY; BLEEDING TENDENCY; BLOOD CLOTTING; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG RESPONSE; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; PHARMACOGENOMICS; PROTEIN C DEFICIENCY; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOPHILIA; VEIN THROMBOSIS; ANIMAL; GENETIC PREDISPOSITION; GENETICS; METABOLISM; TREATMENT OUTCOME;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; RISK FACTORS; TREATMENT OUTCOME; VARIATION (GENETICS); VENOUS THROMBOSIS;

EID: 44949146501     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.4.423     Document Type: Review

References (194)

1. Rosendaal FR: Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb. Haemost. 78, 1-6 (1997).
2. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd: Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch, Intern. Med. 158, 585-593 (1998).
3. Cushman M, Tsai AW, White RH et al.: Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am. J. Med. 117, 19-25 (2004).
4. Rosendaal FR: Venous thrombosis: the role of genes, environment, and behavior. Hematology Am. Soc Hematol. Educ. Program 1-12 (2005).
5. Rosendaal FR: Venous thrombosis: a multicausal disease. Lancet 353, 1167-1173 (1999).
6. Hertzberg MS: Genetic testing for thrombophilia mutations. Semin. Thromb. Hemost. 31, 33-38 (2005).
7. Ariens RA, de Lange M, Snieder H, Boothby M, Spector TD, Grant PJ: Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet 359, 667-671 (2002).
8. Kyrie PA, Eichinger S: Deep vein thrombosis. Lancet 365, 1163-1174 (2005).
9. Wadelius M, Pirmohamed M: Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics jJ. 7, 99-111 (2007).
10. van Boven HH, Lane DA: Antithrombin and its inherited deficiency states. Semin. Hematol. 34, 188-204 (1997).
11. Egeberg O: Inherited antithrombin deficiency causing thrombophilia. Thromb. Diath. Haemorrh. 13, 516-530 (1965).
12. Prochownik EV, Antonarakis S, Bauer KA, Rosenberg RD, Fearon ER, Orkin SH: Molecular heterogeneity of inherited antithrombin III deficiency. N. Engl. J. Med. 308, 1549-1552 (1983).
13. Hara T, Naito K: Inherited antithrombin deficiency and end stage renal disease. Med. Sci. Monit. 11, RA346-RA354 (2005).
14. Franco RF, Reitsma PH: Genetic risk factors of venous thrombosis. Hum. Genet. 109, 369-384 (2001).
15. Corral J, Hernandez-Espinosa D, Soria JM et al.: Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood 109, 4258-4263. (2007).
16. Reitsma PH: Protein C deficiency: from gene defects to disease. Thromb. Haemost. 78, 344-350 (1997).
17. Aiach M, Borgel D, Gaussem P, Emmerich J, Alhenc-Gelas M, Gandrille S: Protein C and protein S deficiencies. Semin. Hematol. 34, 205-216 (1997).
18. Millar DS, Johansen B, Berntorp E et al.: Molecular genetic analysis of severe protein C deficiency. Hum. Genet. 106, 646-653 (2000).
19. Gandrille S, Borgel D, Sala N et al.: Protein S deficiency: a database of mutations - summary of the first update. Thromb. Haemost. 84, 918 (2000).
20. Reitsma PH, Bernardi F, Doig RG et al.: Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb. Haemost. 73, 876-889 (1995).
21. Lane DA, Bayston T, Olds RJ et al.: Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb. Haemost. 77, 197-211 (1997).
22. Stenson PD, Ball EV, Mort M et al.: Human Gene Mutation Database (HGMD): 2003 update. Hum. Mutat. 21, 577-581 (2003).
23. Martinelli I, Mannucci PM, De Stefano V et al.: Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 92, 2353-2358 (1998).
24. Endler G, Mannhalter C: Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. Clin. Chim. Acta 330, 31-55 (2003).
25. Kuhle S, Lane DA, Jochmanns K et al.: Homozygous antithrombinn deficiency Type II (99 Leu to Phe mutation) and childhood thromboembolism. Thromb. Haemost. 86, 1007-1011 (2001).
26. Abu-Amero KK, Owaidah TM, Al-Mahed M: Severe Type I protein C deficiency with neonatal purpura fulminans due to a novel homozygous mutation in exon 6 of the protein C gene. J. Thromb. Haemost. 4, 1152-1153 (2006).
27. Chuansumrit A, Kanogsunthomrat N, Sirachainan N et al.: Negative pressure dressing for promoting wound healing of purpura fulminans in a newborn with homozygous protein C deficiency. Blood Coagul. Fibrinolysis 18, 77-79 (2007).
28. Zivelin A. Griffin JH, Xu X et al.: A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 89, 397-402 (1997).
29. Zivelin A, Rosenberg N, Faier S et al.: A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood 92, 1119-1124 (1998).
30. Shen L, Dahlback B: Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J. Biol. Chem. 269, 18735-18738 (1994).
31. Castoldi E, Rosing J: Factor V Leiden: a disorder of factor V anticoaguiant function. Curr. Opin. Hematol. 11, 176-181 (2004).
32. Nicolaes GA, Dahlback B: Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler. Thromb. Vasc. Biol. 22, 530-538 (2002).
33. Dahlback B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc. Natl Acad Sci. USA 90, 1004-1008 (1993).
34. Bertina RM, Koeleman BP, Koster T et al.: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369, 64-67 (1994)
35. Vos HL: Inherited defects of coagulation Factor V: the thrombotic side. J. Thromb. Haemost. 4, 35-40 (2006).
36. Ridker PM, Miletich JF, Hennekens CH, Buring JE: Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 277, 1305-1307 (1997).
37. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N. Engl. J. Med. 332, 912-917 (1995).
38. Rees DC: The population genetics of factor V Leiden (Arg506Gln). Br. J. Haematol. 95, 579-586 (1996).
39. Emmerich J, Rosendaal FR, Cattaneo M et al.: Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb. Haemost. 86, 809-816 (2001).
40. Bernardi F, Faioni EM, Castoldi E et al.: A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 90, 1552-1557 (1997).
41. Castoldi E, Rosing J, Girelli D et al.: Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma. Thromb. Haemost. 83, 362-265 (2000).
42. Castoldi E, Brugge JM, Nicolaes GA, Girelli D, Tans G, Rosing J: Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood 103, 4173-4179 (2004).
43. Castaman G, Faioni EM, Tosetto A, Bernardi F: The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis. Haematologica 88, 1182-1189 (2003).
44. de Visser MC, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM: The HR2 haplotype of factor V: effects on lector V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb. Haemost. 83, 577-582 (2000).
45. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R: A novel mu6tion df Arg306 of factor V gene in Hong Kong Chinese. Blood 91, 1135-1139 (1998).
46. Williamson D, Brown K, Luddington R, Baglin C, Baglin T: Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C. Blood 91, 1140-1144 (1998).
47. Norstrom E, Thorelli E, Dahlback B: Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood 524, 524-590 (2002).
48. Norstrom EA, Tran S, Steen M, Dahlback B: Effects of factor Xa and protein S on the individual activated protein C-mediated cleavages of coagulation factor Va. J. Biol. Chem. 281, 31486-31494 (2006).
49. Mumford AD, McVey JH, Morse CV et al.: Factor V I359T a novel mutation associated with thrombosis and resistance to activated protein C. Br. J Haematol. 123, 496-501 (2003).
50. Steen M, Norstrom EA, Tholander AL et al.: Functional characterization of factor V-IIe59Thr: a novel mutation associated with thrombosis. Blood 103, 3381-3387 (2004).
51. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothtombin levels and an increase in venous thrombosis. Blood 88, 3698-3703 (1996).
52. Rosendaal FR, Doggen CJ, Zivelin A et al.: Geographic distribution of the 20210 G to A prothrombin variant. Thromb. Haemost. 79, 706-708 (1998).
53. Bosler D, Mattson J, Crisan D: Phenotypic heterogeneity in patients with homozygous prothrombin 20210AA genotype. A paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J. Mol. Diagn. 9, 420-425 (2006).
54. Girolami A, Scarano L, Tormene D, Cella G: Homozygous patients with the 20210 G to A prothrombin polymorphism remain often asymptomatic in spite of the presence of associated risk factors. Clin. Appl. Thromb. Hemost. 7, 122-125 (2001).
55. Danckwardt S, Gehring NH, Neu-Yilik G et al.: The prothrombin 3′ end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations. Blood 104, 428-435 (2004).
56. Gehring NH, Frede U, Neu-Yilik G et al.: Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat. Genet. 28, 389-392 (2001).
57. von Ahsen N, Oellerich M: The intronic prothrombin 19911A>G polymorphism influences splicing efficiency and modulates effect's of the 20210G>A polymorphisrn on mRNA amount and expression in a stable reporter gene assay system. Blood 103, 586-593 (2004).
58. Ceelie H, Spaargaren-van Riel CC, Bertina RM, Ves HL: G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3′-end formation. J. Thromb. Haemost. 2, 119-127 (2004).
59. Soria JM, Almasy L, Souto JC et al.: Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood 95, 2780-2785 (2000).
60. Balim Z, Kosova B, Falzon K, Bezzina Wettinger S, Colak Y: Budd-Chiari syndrome in a patient heterozygous for the point mutation C20221T of the prothrombin gene. J. Thromb. Haemost. 1, 852-853 (2003).
61. Schrijver I, Lenzi TJ, Jones CD, Lay MJ, Druzin ML, Zehnder JL: Prothrombin gene variants in non-Caucasians with fetal loss and intrauterine growth retardation. J. Mol. Diagn. 5, 250-253 (2003).
62. Wylenzek M, Geisen C, Stapenhorst L, Wielckens K, Klingler KR: A novel point mutation in the 3′ region of the prothrombin gene at position 20221 in a Lebanese/Syrian family. Thromb. Haemost. 85, 943-944 (2001).
63. De Stefano V, Martinelli I, Mannucci PM et al.: The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the C20210A prothrombin mutation. N Engl. J. Med. 341, 801-806 (1999).
64. Ceelie H, Bertina RM, van Hylckama Vlieg A, Rosendaal FR, Vos HL: Polymorphisms in the prothrombin gene and their association with plasma prothrombin levels. Thromb. Haemost. 85, 1066-1070 (2001).
65. Perez-Ceballos E, Corral J, Alberca I et al.: Prothrombin A19911G and G20210A polymorphisms' role in thrombosis. Br. J. Haematol. 118, 610-614 (2002).
66. Chinthammitr Y, Vos HL, Rosendaal FR, Doggen CJ: The association of prothrombin A19911G polymorphism with plasma prothrombin activity and venous thrombosis: results of the MEGA study, a large population-based case-control study. J. Thromb. Haemost. 4, 2587-2592 (2006).
67. Martinelli I, Battaglioli T, Tosetto A et al.: Prothrombin A 19911G polymorphism and the risk of venous thromboembolism. J. Thromb. Haemost. 4, 2582-2586 (2006).
68. Reitsma PH, Rosendaal FR: Past and future of genetic research in thrombosis. J. Thromb. Haemost. 5(Suppl. 1), 264-269 (2007).
69. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vandenbroucke JP: Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - the Leiden Thrombophilia Study (LETS). Thromb. Haemost. 71, 719-722 (1994).
70. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR: Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345, 152-155 (1995).
71. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR: High levels of factor IX increase the risk of venous thrombosis. Blood 95, 3678-3682 (2000).
72. Meijers JC. Tekelenburg WL, Bouma BN. Bertina RM, Rosendaal FR: High levels of coagulation factor XI as a risk factor for venous thrombosis. N. Engl. J. Med. 342, 696-701 (2000).
73. Nossent AY, Eikenboom JC, Beetina RM: Plasma coagulation factor levels in venous thrombosis. Semin. Hematol. 44, 77-84 (2007).
74. Bertina RM: Elevated clotting factor levels and venous thrombosis. Pathophysiol. Haemost. Thromb. 33, 395-400 (2003).
75. Kamphuisen PW, Eikenboom JC, Bertina RM: Elevated factor VIII levels and the risk of thrombosis. Arterioscler. Thromb. Vasc. Biol. 21, 731-738 (2001).
76. Kyrle PA, Minar E, Hirschi M et al.: High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N. Engl. J. Med. 343, 457-462 (2000).
77. Rosendaal FR: High levels of factor VIII and venous thrombosis. Thromb. Haemost. 83, 1-2 (2000).
78. Tsai AW, Cushman M, Rosamond WD et al.: Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am. J. Med. 113, 636-642 (2002).
79. Scanavini D, Legnani C, Lunghi B, Mingozzi F, Palareti G, Bernardi F: The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels. Thromb. Haemost. 93, 453-456 (2005).
80. Nossent AY, Eikenboom JC, Vos HL et al.: Haplotypes encoding the factor VIII 1241 Glu variation, factor VIII levels and the risk of venous thrombosis. Thromb. Haemost. 95, 942-948 (2006).
81. Kraaijenhagen RA, in't Anker PS, Koopman MM et al.: High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb. Haemost 83, 5-9 (2000).
82. Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W: Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am. J. Hum. Genet. 37, 89-101 (1985).
83. de Lange M, Snieder H, Ariens RA, Spector TD, Grant PJ: The genetics of haemostasis: a twin study. Lancet 357, 101-105 (2001).
84. Kamphuisen PW, Houwing-Duistermaat JJ, van Houwelingen HC, Eikenboom JC, Bertina RM. Rosendaal FR: Familial clustering of factor VIII and von Willebrand factor levels. Thromb. Haemost. 79, 323-327 (1998).
85. Souto JC, Almasy L, Borrell M et al.: Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 101, 1546-1551 (2000).
86. Berger M, Mattheisen M, Kulle B et al.: High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11. Blood 105, 638-644 (2005).
87. Mansvelt EP, Laffan M, McVey JH, Tuddenham EG: Analysis of the F8 gene in individuals with high plasma factor VIII: C levels and associated venous thrombosis. Thromb. Haemost. 80, 561-565 (1998).
88. Kamphuisen PW, Eikenboom JC, Rosendaal FR et al.: High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br. J. Haematol. 115, 156-158 (2001).
89. Nossent AY, Dai L, Rosendaal FR, Vos HL, Eikenboom JC: β 2 adrenergic receptor polymorphisms: association with factor VIII and von Willebrand factor levels and the risk of venous thrombosis. J. Thromb. Haemost. 3, 405-407 (2005).
90. Bovenschen N, Mertens K, Hu L, Havekes LM, van Vlijmen BJ: LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in wvo. Blood 106, 906-912 0005).
91. Vormittag R, Bencur P, Ay C et al.: Low-density lipoprotein receptor-related protein 1 polymorphism 663 C > T affects clotting factor VIII activity and increases the risk of venous thromboembolism. J. Thromb. Haemost. 5, 497-502 (2007).
92. Henkens CM, Bom VJ, van der Meer J: Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb. Haemost. 74, 1198-1199 (1995).
93. Bezemer ID, Rosendaal FR: Predictive genetic variants for venous thrombosis: what's new? Semin. Hematol. 44, 85-92 (2007).
94. Heit JA, Petterson TM, Owen WG, Burke JP, DE Andrade M, Melton LJ 3rd: Thrombomodulin gene polymorphisms or haplotypes as potential risk factors for venous thromboembolism: a population-based case-control study. J. Thromb. Haemost. 3. 710-717 (2005).
95. Thude H, Wilkens A, Anders O, Barz D: Analysis of the thrombomodulin gene in patients with venous thrombosis. Thromb. Res. 107, 109-114 (2002).
96. Le Flem L, Picard V, Emmerich J et al.: Mutations in promoter region of thrombomodulin and venous thromboembolic disease. Arterioscler. Thromb. Vasc. Biol. 19, 1098-1104 (1999).
97. Le Flem L, Mennen L, Aubry ML et al.: Thrombomodulin promoter mutations, venous thrombosis, and varicose veins. Arterioscler. Thromb. Vasc. Biol. 21, 445-451 (2001).
98. Sugiyama S, Hirota H, Kimura R et al.: Haplotype of thrombomodulin gene associated with plasma thrombomodulin level and deep vein thrombosis in the Japanese population. Thromb. Res. 119, 35-43 (2007).
99. Lammle B, Wuillemin WA, Huber I et al.: Thromboembolism and bleeding tendency in congenital factor XII deficiency - a study on 74 subjects from 14 Swiss families. Thromb. Haemost. 65, 117-121 (1991).
100. Gallimore MJ, Harris SL, Jones DW, Winter M: Plasma levels of factor XII, prekallikrein and high molecular weight kininogen in normal blood donors and patients having suffered venous thrombosis. Thromb. Res. 114, 91-96 (2004).
101. Halbmayer WM, Haushofer A, Radek J, Schon R, Deutsch M, Fischer M: Prevalence of factor XII (Hageman factor) deficiency among 426 patients with coronary heart disease awaiting cardiac surgery. Coron. Artary Dis. 5, 451-454 (1994).
102. Doggen CJ, Rosendaal FR, Meijers JC: Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 108, 4045-4051 (2006).
103. Kanaji T, Okamura T, Osaki K et al.: A common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 91, 2010-2014 (1998).
104. Endler G, Exner M, Mannhalter C et al.: A common C>T polymorphism at nt 46 in the promoter region of coagulation factor XII is associated with decreased factor XII activity. Thromb. Res. 101, 255-260 (2001).
105. Tirado I, Soria JM, Mateo J et al.: Association after linkage analysis Indicates that homozygosity for the 46C>T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis. Thromb. Haemost. 91, 899-904 (2004).
106. Franco RF, Reitsma PH, Lourenco D et al.: Factor XII Va134Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb. Haemost. 81, 676-679 (1999).
107. Zeerleder S, Schloesser M, Redondo M et al.: Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency - a study on 73 subjects from 14 Swiss families. Thromb. Haemost. 82, 1240-1246 (1999).
108. Grunbacher G, Marx-Neuhold E, Pilger E, Koppel H, Renner W: The functional -4C>T polymorphism of the coagulation factor XII gene is not associated with deep venous thrombosis. J. Thromb. Haemost. 3, 2815-2817 (2005).
109. Endler G, Marsik C, Jilma B. Schickbauer T, Quehenberger P, Mannhatter C: Evidence of a U-shaped association between factor XII activity and overall survival. J. Thromb. Haemost. 5, 1143-1148 (2007).
110. Nugent DJ: Prophylaxis in rare coagulation disorders - factor XIII deficiency. Thromb. Res. 118(Suppl. 1), S23-S28 (2006).
111. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ: Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 93, 906-908 (1999).
112. Wells PS, Anderson JL, Scarvelis DK, Doucette SP, Gagnon F: Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis. Am. J. Epidemiol. 164, 101-109 (2006).
113. Balogh I, Szoke G, Karpati L et al.: Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood 96, 2479-2486 (2000).
114. Cushman M, Cornell A, Folsom AR et al.: Associations of the β-fibrinogen Hae III and factor XIII Val34Leu gene variants with venous thrombosis. Thromb. Res. 121(3), 339-345 (2007).
115. Vossen CY, Rosendaal FR: The protective effect of the factor XIII Val34Leu mutation on the risk of deep venous thrombosis is dependent on the fibrinogen level. J. Thromb. Haemost. 3, 1102-1103 (2005).
116. van Hylckama Vlieg A, Rosendaal FR: High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J. Thromb. Haemost. 1. 2677-2678 (2003).
117. Renner W, Cichocki L, Forjanics A, Koppel H, Gasser R, Pilger E: G-455A polymorphism of the fibrinogen β gene and deep vein thrombosis. Eur. J. Clin. Invest. 32, 755-758 (2002).
118. Uitte de Willige S, Rietveld IM, De Visser MC, Vos HL, Bertina RM: Polymorphism 10034C>T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen γ/ γA mRNA ratio. J. Thromb. Haemost. 5, 1243-1249 (2007).
119. Ko YL, Hsu LA, Hsu TS et al.: Functional polymorphisms of FGA, encoding α fibrinogen, are associated with susceptibility to venous thromboembolism in a Taiwanese population. Hum. Genet. 119, 84-91 (2006).
120. Carter AM, Catto AJ, Kohler HP, Ariens RA, Stickland MH, Grant PJ: α-fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood 96, 1177-1179 (2000).
121. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM: Genetic variation in the fibrinogen γ gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen γ' levels. Blood 106, 4176-4183 (2005).
122. Fox EA, Kahn SR: The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb. Haemost. 94, 362-365 (2005).
123. Brull DJ, Serrano N, Zito F et al.: Human CFP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 23, 2063-2069 (2003).
124. Vormittag R, Funk M, Mannhalter C et al.: C-reactive protein 3′ UTR+1444C>T polymorphism in patients with spontaneous venous thromboembolism. Atherosclerosis 188, 406-411 (2006).
125. Blann AD, Nadar SK, Lip GY: The adhesion molecule P-selectin and cardiovascular disease. Eur. Heart J. 24, 2166-2179 (2003).
126. Ay C, Jungbauer LV, Sailer T et al.: High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin. Chem. 53, 1235-1243 (2007).
127. Migliacci R, Becattini C, Pesavento R et al.: Endothelial dysfunction in patients with spontaneous venous thromboembolism. Haematologica 92, 812-818 (2007).
128. Kyrle PA, Hron G, Eichinger S, Wagner O: Circulating P-selectin and the risk of recurrent venous thromboembolism. Thromb. Haemost. 97, 880-883 (2007).
129. Uitte de Willige S, Van Marion V, Rosendaal FR, Vos HL, de Visser MC, Bertina RM: Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis. J. Thromb. Haemost. 2, 1305-1310 (2004).
130. Saposnik B, Reny JL, Gaussem P, Emmerich J, Aiach M, Gandrille S: A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood 103, 1311-1318 (2004).
131. Medina P, Navarro S, Estelles A et al.: Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk. Thromb. Haemost. 91, 905-911 (2004).
132. Medina P, Navarro S, Estelles A, Espana F: Polymorphisms in the endothelial protein C receptor gene and thrombophilia. Thromb. Haemost. 98, 564-569 (2007).
133. Cattaneo M: Hyperhomocysteinemia and venous thromboembolism. Semin. Thromb. Hemost. 32, 716-723 (2006).
134. Cattaneo M: Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb. Haemost. 81, 165-176 (1999).
135. Refsum H, Smith AD, Ueland PM et al.: Facts and recommendations about total homocysteine determinations: an expert opinion. Clin. Chem. 50, 3-32 (2004).
136. den Heijer M, Koster T, Blom HJ et al.: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N. Engl. J. Med. 334, 759-762 (1996).
137. Makris M: Hyperhomocysteinemia and thrombosis. Clin. Lab. Haematol. 22, 133-143 (2000).
138. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM: High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler. Thromb. 14, 1080-1083 (1994).
139. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J: Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am. J. Clin. Nutr. 73, 613-621 (2001).
140. Key NS, McGlennen RC: Hyperhomocyst(e)inemia and thrombophilia. Arch. Pathol. Lab. Med. 126, 1367-1375 (2002).
141. Den Heijer M, Lewington S, Clarke R: Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J. Thromb. Haemost. 3, 292-299 (2005).
142. den Heijer M, Willems HP, Blom HJ et al.: Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 109, 139-144 (2007).
143. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G: Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am. J. Hum. Genet. 43, 414-421 (1988).
144. Frosst P, Blom HJ, Milos R et al.: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10, 111-113 (1995).
145. Jacques PF, Bostom AG, Williams RR et al.: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93, 7-9 (1996).
146. Hustad S, Ueland PM, Vollset SE, Zhang Y, Bjorke-Monsen AL, Schneede J: Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin. Chem. 46, 1065-1071 (2000).
147. Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325, 1202 (2002).
148. Ray JG, Shmorgun D, Chan WS: Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol. Haemost. Thromb. 32, 51-58 (2002).
149. Quinlivan EP, Gregory JF 3rd: Effect of food fortification on folic acid intake in the United States. Am. J. Clin. Nutr. 77, 221-225 (2003).
150. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG: MTHFR677C>T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 288, 2023-2031 (2002).
151. Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR: No association between the common MTHFR677C>T polymorphism and venous thrombosis: results from the MEGA study. Arch. Intern. Med. 167, 497-501 (2007).
152. Reitsma PH: VKORC1 gene variation and venous thrombosis: 'another one bites the dust'? J. Thromb. Haemost. 5, 2017-2019 (2007).
153. Hindorff LA, Heckbert SR, Smith N, Marciante KD, Psaty BM: Common VKORC1 variants are not associated with arterial or venous thrombosis. J. Thromb. Haemost. 5, 2025-2027 (2007).
154. Crawford DC, Ritchie MD, Rieder MJ: Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing. Pharmacogenomics 8, 487-496 (2007).
155. Takahashi H, Wilkinson GR, Nutescu EA et al.: Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16, 101-110 (2006).
156. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E: The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 204S-233S (2004).
157. Hirsh J, Fuster V, Ansell J, Halperin JL: American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J. Am. Coll. Cardiol. 41, 1633-1652 (2003).
158. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ: Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 91, 472-477 (2005).
159. Rost S, Fregin A, Hunerberg M, Bevans CG, Muller CR, Oldenburg J: Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin. Thromb. Haemost. 94, 780-786 (2005).
160. Muraco B, Wolosker M. Neto JB, Leao LE, Kaufmann P: (Surgical considerations on traumatic arteriovenous fistulae of the extremities). AMB Rev. Assoc. Med. Bras. 20, 424-430 (1974).
161. Rettie AE. Korzekwa KR, Kunze KL et al.: Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5, 54-59 (1992).
162. Rettie AE, Tai C: The pharmocogenomics of warfarin: closing in on personalized medicine. Mol, Interv. 6, 223-227 (2006).
163. Sconce EA, Khan TI, Wynne HA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
164. Wadelius M, Chen LY, Downes K et al.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005).
165. Bodin L, Verstuyft C, Tregouet DA et al.: Cytochrome P450 2C9 ( CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106, 135-140 (2005).
166. Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
167. Lee SC, Ng SS, Oldenburg J et al.: Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin. Pharmacol. Ther. 79, 197-205 (2006).
168. Aquilante CL, Langaee TY, Lopez LM et al.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1. and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79, 291-302 (2006).
169. Geisen C, Watzka M, Sittinger K et al.: VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost. 94, 773-779 (2005).
170. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR: Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4, 39-42 (1994).
171. Sullivan-Klose TH, Ghanayem BI, Bell DA et al.: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6, 341-349 (1996).
172. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR: Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6, 429-439 (1996).
173. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F: Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biocbem. Biophys. Res.
174. Sanderson S, Emery J, Higgins J: CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. 7, 97-104 (2005).
175. Rettie AE, Haining RL, Bajpai M, Levy RH: A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res. 35, 253-255 (1999).
176. Ufer M: Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin. Pharmacokinet. 44, 1227-1246 (2005).
177. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW: Identification of the gene for vitamin K epoxide reductase. Nature 427, 541-544 (2004).
178. Rost S, Fregin A, Ivaskevicius V et al.: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency Type 2. Nature 427, 537-541 (2004).
179. Oldenburg J, Watzka M, Rost S, Müller CR: VKORC1: molecular target of coumarins. J Thromb Haemost. 5(Suppl. 1), 1-6 (2007).
180. D'Andrea G, D'Ambrosio RL, Di Perna P et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649 (2005).
181. Yuan HY, Chen JJ, Lee MT et al.: A novel functional VKORC1 promoter polymorphism is associated with interindividual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14, 1745-1751 (2005).
182. Schalekamp T, Brasse BP, Roijers JF et al.: VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin. Pharmacol. Ther. 80, 13-22 (2006).
183. Wadelius M, Chen LY, Eriksson N et al.: Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121, 23-34 (2007).
184. Grody WW, Griffin JH, Taylor AK, Kurf BR, Heit JA: American College of Medical Genetics consensus, statement on factor V Leiden mutation testing. Genet. Med. 3, 139-148 (2001).
185. Varga E: Inherited thrombophilia: key points for genetic counseling. J. Genet. Couns. 16, 261-277 (2007).
186. Wu O, Robertson L, Twaddle S et al.: Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol. Assess. 10, 1-110 (2006).
187. Brenner BR, Nowak-Gottl U, Kosch A, Manco-Johnson M, Laposata M: Diagnostic studies for thrombophilia in women on hormonal therapy and during pregnancy, and in children. Arch. Pathol. Lab. Med. 126, 1296-1303 (2002).
188. Bauer KA: The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann. Intern. Med. 135, 367-373 (2001).
189. Heit JA: Thrombophilia: common questions in laboratory assessment and management. Hematology Am. Soc. Hematol. Educ. Program 2007, 127-135 (2007).
190. Cohn DM, Roshani S, Middeldorp S: Thrombophilia and venous thromboembolism: implications for testing. Semin. Thromb. Hemost. 33, 573-581 (2007).
191. Xu B, Tubbs RR, Kottke-Marchant K: Molecular genetic testing of polymorphisms associated with venous thrombosis: a review of molecular technologies. Diagn. Mol. Pathol. 14, 193-202 (2005).
192. Nicolaides AN, Breddin HK, Carpenter P et al.: Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. Int. Angiol. 24, 1-26 (2005).
193. Flockhart DA, O'Kane D, Williams MS et al.: Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet. Med. 10, 139-150 (2008).
194. Gage BF, Lesko LJ: Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J. Thromb. Thrombolysis 25, 45-51 (2008).